BOLD
Boundless Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BOLD
Boundless Bio, Inc.
A biopharmaceutical company dedicated to developing innovative therapies targeting extrachromosomal DNA (ecDNA)
Biological Technology
04/10/2018
03/28/2024
NASDAQ Stock Exchange
64
12-31
Common stock
9880 Campus Point Drive, Suite 120 San Diego, CA 92121
--
Boundless Bio, Inc., originally founded on April 10, 2018 as Pretzel Therapeutics, Inc., is a Delaware corporation. On July 8, 2019, the company changed its name to Boundless Bio, Inc. They are a clinical-stage oncology company dedicated to unlocking new approaches to cancer therapy, addressing the significant unmet need for oncogene amplification in tumor patients by targeting dyed in vitro DNA (ecDNA), with the root cause of oncogene amplification observed in more than 14% of cancer patients. Their mission is to become a leading biopharmaceutical company, leveraging ecDNA biology to deliver transformative treatments that improve and prolong the lives of patients with previously refractory oncogene-amplified cancer.
Company Financials
EPS
BOLD has released its 2025 Q3 earnings. EPS was reported at -0.62, versus the expected -0.58, missing expectations. The chart below visualizes how BOLD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
